Biofrontera Operating Margin from 2010 to 2026
| BFRI Stock | USD 0.90 0.07 8.72% |
Check Biofrontera financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biofrontera's main balance sheet or income statement drivers, such as Tax Provision of 30.4 K, Interest Income of 88.5 K or Depreciation And Amortization of 944.9 K, as well as many indicators such as Price To Sales Ratio of 0.18, Dividend Yield of 0.0 or PTB Ratio of 1.48. Biofrontera financial statements analysis is a perfect complement when working with Biofrontera Valuation or Volatility modules.
Biofrontera | Operating Margin | Build AI portfolio with Biofrontera Stock |
The Operating Margin trend for Biofrontera offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Biofrontera is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Biofrontera's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Biofrontera over the last few years. It is Biofrontera's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biofrontera's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.90) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Biofrontera Operating Margin Regression Statistics
| Arithmetic Mean | (0.58) | |
| Coefficient Of Variation | (23.30) | |
| Mean Deviation | 0.07 | |
| Median | (0.57) | |
| Standard Deviation | 0.14 | |
| Sample Variance | 0.02 | |
| Range | 0.6257 | |
| R-Value | 0.06 | |
| Mean Square Error | 0.02 | |
| R-Squared | 0 | |
| Significance | 0.82 | |
| Slope | 0 | |
| Total Sum of Squares | 0.29 |
Biofrontera Operating Margin History
About Biofrontera Financial Statements
Investors use fundamental indicators, such as Biofrontera's Operating Margin, to determine how well the company is positioned to perform in the future. Although Biofrontera's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Biofrontera Correlation against competitors. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is there potential for Biotechnology market expansion? Will Biofrontera introduce new products? Factors like these will boost the valuation of Biofrontera. Projected growth potential of Biofrontera fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Biofrontera requires distinguishing between market price and book value, where the latter reflects Biofrontera's accounting equity. The concept of intrinsic value - what Biofrontera's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Biofrontera's price substantially above or below its fundamental value.
It's important to distinguish between Biofrontera's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biofrontera should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biofrontera's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.